



FIG. 1

Results: Primary Efficacy Endpoint
Mean Ocular Itching Scores across all Studies




*P≤0.05; Least Squares Means; Population: ITT + MCMC

FIG. 2
Results: Primary Efficacy Endpoint
Mean Ocular Itching Scores across all Studies



*Statistically Significant; P<0.0025; Population: ITT + LOCF (Phase 2) & ITT + MCMC (Phase 3)

FIG. 3
Results: Primary Efficacy Endpoint
Differences in Ocular Itching Scores across all Studies



*Statistically Significant; P≤0.0025; Population: ITT + LOCF (Phase 2) & ITT + MCMC (Phase 3)




FIG. 4






FIG. 5

**FIG. 6**

Pharmacokinetic Profile of Dexamethasone delivered from a
0.22 mg Dexamethasone Insert

**FIG. 7**




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11